NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Xilio Therapeutics logo
$7.56 +0.05 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$7.52 -0.04 (-0.53%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Xilio Therapeutics Stock (NASDAQ:XLO)

Advanced

Key Stats

Today's Range
$7.07
▼
$7.60
50-Day Range
$7.31
▼
$9.24
52-Week Range
$6.47
▼
$10.71
Volume
20,100 shs
Average Volume
31,521 shs
Market Capitalization
$53.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Hold

Company Overview

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research centers on therapies designed to become active primarily within tumors, with the goal of directing immune activity toward cancer while limiting effects on healthy tissue.

The company’s research programs include engineered antibody and cytokine-based candidates intended to stimulate the immune system’s response to tumors. Xilio advances these programs through preclinical research and clinical development; its candidates are investigational and have not been established as approved treatments.

Founded in 2016, Xilio is based in Massachusetts and participates in the global biotechnology and oncology research sector. Its work is focused on developing potential cancer therapies rather than providing commercial products or services to patients.

AI Generated. May Contain Errors.

Xilio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

XLO MarketRank™: 
2.170691547745 of 5 stars

Xilio Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 650th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xilio Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Xilio Therapeutics has a consensus price target of $16.00, representing about 111.6% upside from its current price of $7.56.

  • Amount of Analyst Coverage

    Xilio Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Xilio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.95) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -18.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -18.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.29% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently decreased by 4.39%, indicating that investor sentiment is improving.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

    • Insider Buying vs. Insider Selling

      In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      7.45% of the stock of Xilio Therapeutics is held by insiders.

    • Percentage Held by Institutions

      54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Xilio Therapeutics' insider trading history.
    Receive XLO Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    XLO Stock News Headlines

    Drop these 5 stocks before the market opens tomorrow!
    The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
    Xilio Names Yariv Houvras Chief Medical Officer
    See More Headlines

    XLO Stock Analysis - Frequently Asked Questions

    Xilio Therapeutics' stock was trading at $8.9628 on January 1st, 2026. Since then, XLO stock has decreased by 15.7% and is now trading at $7.56.

    Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its earnings results on Tuesday, November, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.64. The business earned $9.98 million during the quarter, compared to the consensus estimate of $4.92 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 60.54% and a negative net margin of 20.89%.

    Shares of Xilio Therapeutics reverse split on the morning of Friday, March 13th 2026.The 1-14 reverse split was announced on Thursday, March 12th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

    Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

    Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include NVIDIA (NVDA), Archer Aviation (ACHR), Alibaba Group (BABA), BigBear.ai (BBAI), Berkshire Hathaway (BRK.B), Coeur Mining (CDE) and Walt Disney (DIS).

    Company Calendar

    Last Earnings
    11/10/2026
    Today
    11/20/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:XLO
    CIK
    1840233
    Fax
    N/A
    Employees
    76
    Year Founded
    2015

    Price Target and Rating

    High Price Target
    $16.00
    Low Price Target
    $16.00
    Potential Upside/Downside
    +113.2%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.40)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$35.04 million
    Net Margins
    -20.89%
    Pretax Margin
    -20.89%
    Return on Equity
    -60.54%
    Return on Assets
    -24.76%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.72
    Quick Ratio
    4.72

    Sales & Book Value

    Annual Sales
    $43.77 million
    Price / Sales
    1.21
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $9.66 per share
    Price / Book
    0.78

    Miscellaneous

    Outstanding Shares
    7,060,000
    Free Float
    6,538,000
    Market Cap
    $52.99 million
    Optionable
    Not Optionable
    Beta
    -0.13

    Social Links

    7 Energy Stocks to Buy and Hold Forever Cover

    Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

    Get This Free Report

    This page (NASDAQ:XLO) was last updated on 11/20/2026 by MarketBeat.com Staff.
    From Our Partners